Literature DB >> 12389712

Annexin V does not represent a diagnostic alternative to myoglobin for early detection of myocardial infarction.

Dirk Peetz1, Gerd Hafner, Stefan Blankenberg, Ali Asghar Peivandi, Rosemarie Schweigert, Karin Brunner, Manfred Dahm, Hans J Rupprecht, Martin Möckel.   

Abstract

Annexin V is a calcium binding protein, which is widely present in various cells and tissues. Due to an early release reaction after myocardial injury the determination of annexin V might be useful for the rapid diagnosis of acute myocardial infarction. An enzyme-linked immunosorbent assay was used to measure annexin V in comparison to myoglobin in samples from healthy individuals, patients suffering from acute or chronic liver, renal, and pulmonary diseases as well as acute coronary syndromes and aortocoronary bypass surgery. Increased myoglobin and annexin V concentrations were observed 80 and 140 (maximum) minutes after myocardial ischemia induced by percutaneous transluminal coronary angioplasty. For the diagnosis of myocardial infarction annexin V (cutoff-level: 5.9 microg/L) showed a slightly higher sensitivity than myoglobin (annexin V: 74.5%; myoglobin: 59.6%), but specificity was much lower (annexin V: 39%; myoglobin: 82.5%). The area under the curve of a ROC analysis demonstrated that annexin V cannot be used as an early marker for the diagnosis of acute coronary syndromes. Increased annexin V levels are induced by several diseases, leading to a low specificity for the diagnosis of a myocardial injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389712

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  3 in total

1.  Evaluation of plasma annexin V levels in children and young adults with solid tumors.

Authors:  Mark A Applebaum; Elise Sambrano; Sharon Lee; Robert Goldsby; Katherine K Matthay; Steven G DuBois
Journal:  Int J Biol Markers       Date:  2012-07-19       Impact factor: 2.659

Review 2.  Imaging of apoptosis in the heart with nanoparticle technology.

Authors:  Howard H Chen; Lee Josephson; David E Sosnovik
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011 Jan-Feb

3.  A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption.

Authors:  Regent Lee; Roman Fischer; Philip D Charles; David Adlam; Alessandro Valli; Katalin Di Gleria; Rajesh K Kharbanda; Robin P Choudhury; Charalambos Antoniades; Benedikt M Kessler; Keith M Channon
Journal:  Clin Proteomics       Date:  2017-06-19       Impact factor: 3.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.